NYSE:NVRO Nevro - NVRO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $36.68 +0.23 (+0.63%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$36.14▼$37.2550-Day Range$35.60▼$47.9052-Week Range$34.70▼$78.90Volume495,977 shsAverage Volume583,945 shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$54.58 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nevro MarketRank™ ForecastAnalyst RatingHold1.93 Rating ScoreUpside/Downside48.8% Upside$54.58 Price TargetShort InterestBearish9.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.72) to ($2.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector643rd out of 1,054 stocksSurgical & Medical Instruments Industry67th out of 105 stocks 4.0 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Hold. The company's average rating score is 1.93, and is based on 3 buy ratings, 7 hold ratings, and 4 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.58, Nevro has a forecasted upside of 48.8% from its current price of $36.68.Amount of Analyst CoverageNevro has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.00% of the float of Nevro has been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Nevro has recently increased by 9.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVRO. Previous Next 2.3 News and Social Media Coverage News SentimentNevro has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Nevro this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Nevro to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Nevro is held by insiders.Percentage Held by Institutions96.03% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to grow in the coming year, from ($2.72) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -111.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -111.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nevro (NYSE:NVRO) StockNevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.Read More Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address NVRO Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comWilliam Blair Comments on Nevro Corp.'s Q1 2023 Earnings (NYSE:NVRO)January 27, 2023 | americanbankingnews.comPiper Sandler Trims Nevro (NYSE:NVRO) Target Price to $37.00January 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 21, 2023 | americanbankingnews.comNevro (NYSE:NVRO) Cut to Hold at StockNews.comJanuary 21, 2023 | americanbankingnews.comNevro Corp. (NYSE:NVRO) Receives $54.67 Average Price Target from AnalystsJanuary 19, 2023 | finance.yahoo.comNevro to Report Fourth Quarter and Full-Year 2022 Financial ResultsJanuary 19, 2023 | americanbankingnews.comNevro (NYSE:NVRO) versus Calmare Therapeutics (OTCMKTS:CTTC) Head-To-Head ReviewJanuary 12, 2023 | finance.yahoo.comNevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual MeetingJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 11, 2023 | finance.yahoo.comNevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 OutlookJanuary 9, 2023 | finance.yahoo.comNevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue GuidanceDecember 19, 2022 | finance.yahoo.comNevro to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 14, 2022 | finance.yahoo.comNevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual MeetingNovember 21, 2022 | finance.yahoo.comInsiders may be rethinking their US$2.3m Nevro Corp. (NYSE:NVRO) investment now that the company has lost US$51m in valueNovember 3, 2022 | finance.yahoo.comNevro (NVRO) Q3 Earnings Beat Estimates, 2022 View RevisedOctober 27, 2022 | finance.yahoo.com4 MedTech Stocks Set to Outpace Q3 Earnings EstimatesOctober 13, 2022 | finance.yahoo.comNevro Secures FDA Nod HFX iQ Spinal Cord Stimulation System For to Personalize Pain TreatmentOctober 13, 2022 | benzinga.comNevro Late Wednesday Announces FDA Approval Of HFX iQ Spinal Cord Stimulation System To Personalize The Treatment of Chronic Pain - Nevro (NYSE:NVRO) - BenzingaOctober 13, 2022 | streetinsider.comNevro (NVRO) Announces FDA Approval of HFX iQ Spinal Cord Stimulation System - StreetInsider.comOctober 12, 2022 | marketwatch.comNevro Shares Rise 5%, FDA Approves HFX iQ Spinal Cord Stimulation System - MarketWatchOctober 12, 2022 | finance.yahoo.comNevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic PainOctober 12, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About NevroOctober 11, 2022 | finance.yahoo.comInvestors are selling off Nevro (NYSE:NVRO), lack of profits no doubt contribute to shareholders one-year lossOctober 10, 2022 | finance.yahoo.comNevro Comments on UnitedHealthcare Medical Coverage Policy UpdateOctober 6, 2022 | seekingalpha.comNevro down 9% after UnitedHealth won't cover spinal cord stimulation for some indications - Seeking AlphaOctober 5, 2022 | in.investing.comCiti Opens a Positive Catalyst Watch on DexCom, Negative on Nevro, Cuts Penumbra to Neutral By Investing.com - Investing.com IndiaOctober 4, 2022 | finance.yahoo.comNevro Announces FDA Approval of Costa Rica Manufacturing OperationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address NVRO Company Calendar Last Earnings11/02/2022Today1/28/2023Next Earnings (Confirmed)2/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVRO CUSIPN/A CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees945Year FoundedN/APrice Target and Rating Average Stock Price Forecast$54.58 High Stock Price Forecast$95.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+48.8%Consensus RatingHold Rating Score (0-4)1.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,360,000.00 Net Margins-2.01% Pretax Margin-1.80% Return on Equity-40.89% Return on Assets-20.09% Debt Debt-to-Equity Ratio0.57 Current Ratio7.05 Quick Ratio5.82 Sales & Book Value Annual Sales$386.90 million Price / Sales3.36 Cash FlowN/A Price / Cash FlowN/A Book Value$8.70 per share Price / Book4.22Miscellaneous Outstanding Shares35,430,000Free Float34,438,000Market Cap$1.30 billion OptionableOptionable Beta0.86 Key ExecutivesD. Keith GrossmanChairman, President & Chief Executive OfficerRoderick H. MacLeodChief Financial OfficerDavid CarawayChief Medical OfficerChristopher ChristoforouVice President-Technical OperationsStephen SmithVice President-Information TechnologyKey CompetitorsAlphatecNASDAQ:ATECTreace Medical ConceptsNASDAQ:TMCIEmbectaNASDAQ:EMBCBeauty HealthNASDAQ:SKINParagon 28NYSE:FNAView All CompetitorsInsiders & InstitutionsExchange Traded Concepts LLCBought 936 shares on 1/18/2023Ownership: 0.091%Assenagon Asset Management S.A.Bought 69,616 shares on 1/12/2023Ownership: 0.624%Bank of New York Mellon CorpSold 183,483 shares on 12/8/2022Ownership: 0.423%California State Teachers Retirement SystemSold 789 shares on 11/21/2022Ownership: 0.120%M&T Bank CorpBought 1,398 shares on 11/17/2022Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions NVRO Stock - Frequently Asked Questions Should I buy or sell Nevro stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares. View NVRO analyst ratings or view top-rated stocks. What is Nevro's stock price forecast for 2023? 14 Wall Street research analysts have issued 1-year price objectives for Nevro's stock. Their NVRO share price forecasts range from $31.00 to $95.00. On average, they predict the company's stock price to reach $54.58 in the next year. This suggests a possible upside of 48.8% from the stock's current price. View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts. How have NVRO shares performed in 2023? Nevro's stock was trading at $39.60 at the start of the year. Since then, NVRO stock has decreased by 7.4% and is now trading at $36.68. View the best growth stocks for 2023 here. When is Nevro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023. View our NVRO earnings forecast. How can I listen to Nevro's earnings call? Nevro will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) posted its quarterly earnings data on Wednesday, November, 2nd. The medical equipment provider reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. The medical equipment provider had revenue of $100.47 million for the quarter, compared to analyst estimates of $99.08 million. Nevro had a negative net margin of 2.01% and a negative trailing twelve-month return on equity of 40.89%. What guidance has Nevro issued on next quarter's earnings? Nevro updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $406.40 million-$406.40 million, compared to the consensus revenue estimate of $405.14 million. What is D. Keith Grossman's approval rating as Nevro's CEO? 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG). What is Nevro's stock symbol? Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO." Who are Nevro's major shareholders? Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.62%) and Exchange Traded Concepts LLC (0.09%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nevro's stock price today? One share of NVRO stock can currently be purchased for approximately $36.68. How much money does Nevro make? Nevro (NYSE:NVRO) has a market capitalization of $1.30 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131,360,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. How many employees does Nevro have? The company employs 945 workers across the globe. How can I contact Nevro? Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com. This page (NYSE:NVRO) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.